The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes
Abstract Background Molecular-clinical prognostic models for Myelodysplastic syndromes (MDS) offer more accurate prognosis predictions, yet existing models often overlook the heterogeneity of mutational profiles against the cytogenetic background. Moreover, how to apply these models in regions where...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Journal of Translational Medicine |
| Online Access: | https://doi.org/10.1186/s12967-024-05995-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594514148065280 |
|---|---|
| author | Wei Wang Yudi Zhang Wenli Yang Xiaozhen Liu Lingxu Jiang Wei Lang Yingwan Luo Xinping Zhou Lu Wang Li Ye Ying Xu Liya Ma Hongyan Tong |
| author_facet | Wei Wang Yudi Zhang Wenli Yang Xiaozhen Liu Lingxu Jiang Wei Lang Yingwan Luo Xinping Zhou Lu Wang Li Ye Ying Xu Liya Ma Hongyan Tong |
| author_sort | Wei Wang |
| collection | DOAJ |
| description | Abstract Background Molecular-clinical prognostic models for Myelodysplastic syndromes (MDS) offer more accurate prognosis predictions, yet existing models often overlook the heterogeneity of mutational profiles against the cytogenetic background. Moreover, how to apply these models in regions where large panel NGS is unaffordable remains a significant challenge to be addressed. Methods A total of 237 NK MDS patients from our center were used as the training set to screen for key variables and develop a prognostic model with overall survival (OS) as the endpoint. The C-index was used as the main evaluation metric to assess the model’s performance. The IWG-PM cohort (n = 691) was used as an external independent validation set to evaluate the generalizability of the model. Results We developed a seven-parameter molecular-clinical prognostic model, the Molecular Prognostic Scoring System for NK MDS (NK-PSS-M), which only incorporates three gene mutations as parameters. The NK-PSS-M can reliably predict OS and leukemia-free survival (LFS). The performance of NK-PSS-M was comparable to that of the Molecular International Prognostic Scoring System (IPSS-M), and it significantly outperformed the Revised International Prognostic Scoring System for MDS (IPSS-R). Conclusions The NK-PSS-M model improved the risk stratification of non-molecular models and provided a reliable alternative to the IPSS-M. This strategy provides insights into how resource-scarce regions can apply molecular-clinical models. |
| format | Article |
| id | doaj-art-d6655edd334945de9725aa86354f12e5 |
| institution | Kabale University |
| issn | 1479-5876 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj-art-d6655edd334945de9725aa86354f12e52025-01-19T12:37:15ZengBMCJournal of Translational Medicine1479-58762025-01-0123111410.1186/s12967-024-05995-xThe molecular prognostic scoring system for normal karyotype myelodysplastic syndromesWei Wang0Yudi Zhang1Wenli Yang2Xiaozhen Liu3Lingxu Jiang4Wei Lang5Yingwan Luo6Xinping Zhou7Lu Wang8Li Ye9Ying Xu10Liya Ma11Hongyan Tong12Department of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineAbstract Background Molecular-clinical prognostic models for Myelodysplastic syndromes (MDS) offer more accurate prognosis predictions, yet existing models often overlook the heterogeneity of mutational profiles against the cytogenetic background. Moreover, how to apply these models in regions where large panel NGS is unaffordable remains a significant challenge to be addressed. Methods A total of 237 NK MDS patients from our center were used as the training set to screen for key variables and develop a prognostic model with overall survival (OS) as the endpoint. The C-index was used as the main evaluation metric to assess the model’s performance. The IWG-PM cohort (n = 691) was used as an external independent validation set to evaluate the generalizability of the model. Results We developed a seven-parameter molecular-clinical prognostic model, the Molecular Prognostic Scoring System for NK MDS (NK-PSS-M), which only incorporates three gene mutations as parameters. The NK-PSS-M can reliably predict OS and leukemia-free survival (LFS). The performance of NK-PSS-M was comparable to that of the Molecular International Prognostic Scoring System (IPSS-M), and it significantly outperformed the Revised International Prognostic Scoring System for MDS (IPSS-R). Conclusions The NK-PSS-M model improved the risk stratification of non-molecular models and provided a reliable alternative to the IPSS-M. This strategy provides insights into how resource-scarce regions can apply molecular-clinical models.https://doi.org/10.1186/s12967-024-05995-x |
| spellingShingle | Wei Wang Yudi Zhang Wenli Yang Xiaozhen Liu Lingxu Jiang Wei Lang Yingwan Luo Xinping Zhou Lu Wang Li Ye Ying Xu Liya Ma Hongyan Tong The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes Journal of Translational Medicine |
| title | The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes |
| title_full | The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes |
| title_fullStr | The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes |
| title_full_unstemmed | The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes |
| title_short | The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes |
| title_sort | molecular prognostic scoring system for normal karyotype myelodysplastic syndromes |
| url | https://doi.org/10.1186/s12967-024-05995-x |
| work_keys_str_mv | AT weiwang themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT yudizhang themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT wenliyang themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT xiaozhenliu themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT lingxujiang themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT weilang themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT yingwanluo themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT xinpingzhou themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT luwang themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT liye themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT yingxu themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT liyama themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT hongyantong themolecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT weiwang molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT yudizhang molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT wenliyang molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT xiaozhenliu molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT lingxujiang molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT weilang molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT yingwanluo molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT xinpingzhou molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT luwang molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT liye molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT yingxu molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT liyama molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes AT hongyantong molecularprognosticscoringsystemfornormalkaryotypemyelodysplasticsyndromes |